SelectScience
Join Free
Accelerating Science
NewsLife Sciences

CardiNor announces CE marking and launch of new Cardiovascular risk marker: The CardiNor Secretoneurin ELISA test

CardiNor AS
15 Mar 2022
Ellie Abbott
Biochemist

Product news

Cardiovascular DX company CardiNor AS has announced that it has achieved CE marking according to IVDD for the CardiNor Secretoneurin ELISA test.

This important new frontline biomarker for cardiovascular disease reflects the biological mechanism triggering arrhythmia. CardiNor has a comprehensive clinical program to further strengthen and widening the clinical documentation of its novel biomarker, and the CardiNor Secretoneurin (SN) test is being trialled in patient selection for cardiac rhythm management using Implantable Cardiac Defibrillator (ICD) devices.

SN is the only biomarker shown to be associated with biological processes linked to cardiomyocyte handling and has been described as the “missing link biomarker” in cardiovascular disease risk assessment. This unique biological function may explain why SN is an independent and strong predictor of mortality in all major patient cohorts tested, including patients with ventricular arrhythmia, acute heart failure, and acute respiratory failure patients with CVD and severe sepsis.

“We are delighted to achieve CE marking on this important new biomarker and are now looking forward to expanding our distribution network globally and to prepare for US market entry. The COVID-19 pandemic has further highlighted the need for improved cardiovascular disease risk markers. The CardiNor Secretoneurin ELISA assay will provide clinicians with a key tool for both more accurate risk prediction and patient management.” commented Dag Christiansen, CEO, CardiNor.

The CardiNor SN assay is based on work by Professor Torbjørn Omland and his research group at Akershus University Hospital in Norway who recently received the prestigious Jebsen award and additional funding to further expand their work on biomarkers linked to sudden cardiac arrest.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Links

CardiNor AS

Tags

ELISAEnzyme-linked immunosorbent assays (ELISA), also known as enzyme immunoassays (EIA), are used for the detection and quantification of proteins, peptides and antibodies in a sample. ELISA often comes in kit format, with pre-selected antibody pairs to detect specific proteins or biomarkers of diseases such as diabetes and obesity, or cardiovascular and neurological disorders. Detection is made possible with chemiluminescent, fluorescent or colorimetric substrates and detection instruments such as microplate / ELISA readers. Other kits available include: Enzyme-linked immunospot (ELISPOT) assays for the quantification of protein-producing cells and chemiluminescent immunoassays (CLIA) kits. Find the best ELISA kits and products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.BiomarkersBiomarkers are biological markers which can be measured and evaluated to indicate a biological state. The use of biomarkers in research and diagnosis can indicate a normal or disease state or drug response of cells / tissues. Biomarkers include genetic markers, cell surface markers such as antigens, antibodies or receptors and secreted molecules such as cytokines. An assay system is required for identification of biomarkers. :CardiologyCardiovascular DiseaseCardiovascular disease refers to a group of disorders of the heart and blood vessels, including heart attacks, strokes, and high blood pressure. Early diagnosis and effective treatment are essential for improving patient outcomes. Explore cardiovascular disease research and diagnostic tools in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.Biomarker DiscoveryClinical biomarkers refer to substances related to known medical conditions that can be accurately measured <i>in vitro</i>. Biomarkers can be used to diagnose presence of a disease and indicate disease severity. The discovery of new biomarkers is incredibly valuable in the field of diagnostics.

Related articles

CardiNor announces CE marking and launch of new Cardiovascular risk marker: The CardiNor Secretoneurin ELISA test